TL;DR
A MedPage Today neurology roundup highlights a New York Times examination of alcohol’s effects on the brain, projections that tau-targeting Alzheimer’s drugs could reach $70 billion in value, a failed ALS drug trial, and a Nature study showing mice integrated transplanted human cortical organoids.
A weekly roundup of neurology and neuroscience news published by MedPage Today on September 29, 2026 highlights developments including alcohol’s effects on the brain, projections that tau-targeting drugs could be the next frontier in Alzheimer’s disease treatment, a failed ALS drug candidate, and a Nature study in which mice integrated transplanted human stem cell-derived cortical organoids. The roundup, written by deputy managing editor Judy George, compiles findings from peer-reviewed journals and industry announcements.
Among the research findings summarized: an international longitudinal study published in The Lancet showed that epilepsy incidence rose sharply after symptomatic Alzheimer’s disease onset in people with Down syndrome. A Canadian cohort study in the journal Neurology found that transient ischemic attacks were associated with a large and sustained increase in dementia risk.
A large U.S. study, also published in Neurology, reported that stroke rates among adults ages 20 to 54 nearly doubled over a 27-year period, coinciding with increases in both vascular risk factors and substance abuse, according to the roundup. Separately, data from the HEALEY ALS platform trial published in JAMA Network Open showed that DNL343, a brain-penetrant drug designed to inhibit the integrated stress response, did not show benefit in amyotrophic lateral sclerosis.
On the industry side, uniQure said ongoing phase I/II studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease showed continued slowing of disease progression, but effects were not significant at 4 years compared with a natural history cohort. An investment banking firm reported, according to Axios, that tau-targeting drugs may be the next frontier in Alzheimer’s treatment with an expected value as high as $70 billion. In Nature, researchers reported that mice engineered to lack a cerebral cortex successfully integrated transplanted human stem cell-derived cortical organoids. The roundup also noted that two women who provided autism therapy services were arrested and charged with defrauding the Connecticut Medicaid Health Insurance Program, according to the state’s division of criminal justice.
Why These Findings Matter for Patients
The collection of studies touches several major areas of neurological care. The reported near-doubling of stroke rates in younger adults, if confirmed, points to a shifting burden of vascular disease toward people in midlife, with implications for prevention and screening. The link between transient ischemic attacks and sustained dementia risk adds to evidence that even temporary interruptions of blood flow can have long-term cognitive consequences.
For patients with ALS and Huntington’s disease, the roundup carries mixed news: DNL343 showed no benefit in the HEALEY platform trial, while uniQure reported continued slowing of Huntington’s progression with AMT-130 — though the company itself said the 4-year effects were not significant against a natural history comparison. The projection of up to $70 billion in value for tau-targeting Alzheimer’s drugs signals where investment is flowing as the field moves beyond amyloid-targeting therapies.
Top picks for "brain alcohol next"
As an affiliate, we earn on qualifying purchases.
The Week’s Reporting Sources
The roundup aggregates findings from The Lancet, Neurology, JAMA Network Open, and Nature, alongside reporting from The New York Times on what alcohol does to the brain and what amount, if any, may be safe, and from Axios on the investment outlook for tau-targeting Alzheimer’s drugs. Company announcements included uniQure’s update on AMT-130.
The Connecticut criminal justice case involves two women who provided autism therapy services and were charged with defrauding the state’s Medicaid Health Insurance Program. The item was included as part of the week’s neurology-adjacent news.
“Ongoing phase I/II studies of AMT-130 in Huntington’s disease showed continued slowing of disease progression, but effects were not significant at 4 years compared with a natural history cohort.”
— uniQure
What the Roundup Leaves Open
Most items are brief summaries, and full details — study sizes, effect magnitudes, and confidence intervals — reside in the underlying journal articles. The New York Times alcohol examination asks what amount, if any, may be safe, a question that remains scientifically unsettled. The $70 billion figure for tau-targeting drugs is an investment bank’s projection of expected value, not evidence of clinical efficacy, and no tau-targeting drug is described as approved in the roundup.
The mice study raises the question of how well human cortical organoids integrated into animal brains model human brain function and disease; that was not addressed in the summary. The relationship between the rising stroke rates and the noted rise in vascular risk factors and substance abuse is described as coinciding, not as established causation.
Follow-Up Research and Trials to Watch
The underlying journal studies — in The Lancet, Neurology, JAMA Network Open, and Nature — will inform follow-up work in their respective fields. uniQure’s AMT-130 phase I/II program in Huntington’s disease continues, and longer-term data will be needed to determine whether the observed slowing becomes statistically significant. In Alzheimer’s disease, tau-targeting programs are the subject of ongoing development, and clinical readouts will test the investment projections. The Connecticut Medicaid fraud case will proceed through the courts.
Key Questions
What did the roundup say about alcohol and the brain?
The New York Times examined what alcohol does to the brain and what amount, if any, may be safe. The roundup did not report a definitive safe threshold, and the question remains unsettled.
Why are tau-targeting drugs called the next Alzheimer’s frontier?
According to an investment banking firm cited by Axios, tau-targeting drugs may be the next frontier in Alzheimer’s treatment, with an expected value as high as $70 billion. This is a market projection, not proof of clinical benefit.
Did the ALS drug DNL343 work?
No. Data from the HEALEY ALS platform trial published in JAMA Network Open showed DNL343, a brain-penetrant integrated stress response inhibitor, did not show benefit in amyotrophic lateral sclerosis.
What happened in the mice with human brain cells?
A Nature study reported that mice engineered to lack a cerebral cortex successfully integrated transplanted human stem cell-derived cortical organoids — lab-grown clusters of human cortical tissue.
Is AMT-130 proven effective for Huntington’s disease?
No. uniQure reported continued slowing of disease progression in phase I/II studies, but said effects were not significant at 4 years compared with a natural history cohort.
Source: rss
